Unveiling the role of p62 at modulating astrocyte reactivity and its implications for ALS/FTD

MRC · United Kingdom government procurement

This opportunity is now closed. GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

Closed
Status

Opportunity Overview

Amyotrophic lateral sclerosis (ALS) is a fatal late-onset neurodegenerative disease that targets the function and survival of motor neurons in the spinal cord and cortex (1). Notably, ALS shares numerous genetic, clinical, and pathological features with frontotemporal dementia (FTD), leading to their recognition as part of a disease spectrum termed ALS/FTD. Currently, no disease-modifying treatments are available for these devastating illnesses (1).

The accumulation of protein aggregates is a major hallmark of ALS and FTD, suggesting the compromise of protein clearance pathways in the pathogenesis of these diseases (2). One of the ALS/FTD-linked genes encodes sequestosome 1 (SQSTM1/p62), a multi-domain scaffold protein involved in targeting cargo for degradation via autophagy and the ubiquitin-proteasome system. Additionally, p62 serves as a signalling hub for various cellular signal transduction cascades, thereby regulating multiple cellular functions, including the activation of mTORC1 in nutrient sensing, the regulation of inflammation and apoptosis through activation of the nuclear factor kappa-B and the antioxidant response via activation of Keap1-NF-E2-related factor 2 (Nrf2) pathway (3).

Although less extensively investigated, the presence of p62-positive inclusions is not limited to neurons but also extends to astrocytes in the temporal cortex of patients with ALS/FTD (4,5,6,7), as well as astrocytes from FTD cases (8,9) and glial cells in human tauopathies and synucleopathies (10). Despite some evidence, a detailed characterization of the pathology associated with astrocytic p62 in ALS/FTD is currently missing.

In neurodegenerative diseases like ALS and FTD, astrocytes become reactive as part of a conserved physiological response that ultimately result in the gain of new functions and loss or upregulation of homeostatic ones (11). In ALS and FTD, reactive astrocytes contribute to neuron toxicity through non-cell autonomous effects (12). When we modelled...

Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch Development
PublishedSeptember 30, 2022
Procurement stageActive solicitation
ClosedClosing date not published
StatusClosed — no longer accepting responses
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Browse Similar Open Opportunities in United Kingdom

Global Travel, Accommodation and Venue Management Services
NEPRO Total Talent
Capital Programme Delivery Framework(s)
Technology Products and Associated Services 3
Technology Products and Associated Services 3
Workforce Solution 2
GMCA 2201 NW Regional Children’s Services Contract
Integrated Partnerships Framework

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.